NIFTY 50

Expect 25-26% EBITDA margins going forward, says Dr Lal Pathlabs

Updated : February 11, 2019 01:19 PM IST

The third quarter numbers looked in-line for Dr Lal PathLabs with revenues up 11.3 percent year-on-year (YoY) to Rs 292.5 crore versus Rs 262.7 crore. The YoY EBITDA was up 16 percent and margins were up 22.43 percent. Profit increased by 27 percent.

Elaborating on the numbers, Ved Goel, CFO of the company, said the revenue growth in the quarter was driven by volumes. For the quarter, volume growth was 12.1 percent and year to date it is 16 percent, he said, adding the revenue per patient has increased.

The company has also been able to maintain its margins despite competition, said Goel, adding that going forward it expects normalised EBITDA margins to be in the range of 25-26 percent.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV